LC002 is in Phase 3 development as a therapeutic HIV vaccine.
(Compound details obtained from Research Toward a Cure website1 and Genetic Immunity website2)
What is LC002?
LC002 is an investigationalthat is being studied as a possible strategy to treat people living with HIV. LC002 belongs to a group of HIV vaccines called therapeutic HIV vaccines.1
How do therapeutic HIV vaccines work?
A What is a Therapeutic HIV Vaccine? fact sheet.is a type of vaccine that’s designed to improve the body’s to HIV in a person living with HIV.3 Therapeutic vaccines may be able to reduce the amount of HIV in the body and help keep HIV at undetectable levels without the need for the regular use of (ART).4 To learn more, read the HIVinfo
There are several types of therapeutic vaccines currently being studied to treat HIV. LC002 is a DNA vaccine developed using HIV’s genetic information. The aim of the vaccine is to produce an immune response against HIV in the body.5
Which clinical trials are studying LC002?
Study Names: ACTG 5176; A5176; NCT00270205
Status: This study has been completed.
Location: United States
Purpose: The purpose of this study was to evaluate the safety of LC002 and its ability to produce an immune response in people with .6,7
Study Names: GIEU006; NCT00711230
Status: This study has been completed.
Purpose: The purpose of this study was to evaluate the safety of LC002 and its ability to produce an immune response in people with HIV who have never taken HIV medicines. This study also looked at LC002’s ability to reduce levels.1,8
Study Name: GIRU001
Status: This study is ongoing.
Purpose: The purpose of this study is to evaluate the ability of LC002 to produce an immune response and reduce viral load levels in people with HIV who have never taken HIV medicines.2
For more details on the studies listed above, see the Health Professional version of this drug summary.
Additional clinical trials evaluating LC002 have also been completed, including a NCT00918840) that looked at LC002’s ability to produce an immune response in the body and its impact on viral load levels during a of ART.9(
What side effects might LC002 cause?
One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in some of the studies of LC002 listed above.ACTG 5176 (NCT00270205):
In this study, the most common side effects reported by participants were general body complaints, such as aches, pain, discomfort, fatigue, or fever. Some participants had skin reactions, such as itchiness and rash, as well as abnormal blood tests. All LC002-related side effects that occurred during the trial were mild or moderate in severity. None of the participants stopped or changed their treatment because of a side effect.6GIEU006 (NCT00711230):
All side effects reported by participants in this study were considered mild or moderate. None of the participants stopped treatment because of side effects. Only one side effect (limb pain under stress) was possibly related to LC002, but this side effect went away before the end of the study.10
Because LC002 is still being studied, information on possible side effects of the vaccine is not complete. As testing of LC002 continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying LC002?
More information about LC002-related research studies is available from ClinicalTrials.gov.
Some clinical trials may be looking for volunteer participants. Your health care provider can help you decide whether participating in a NIH Clinical Research Trials and You.is right for you. For more information, visit
- Treatment Action Group website. Research toward a cure trials. http://www.treatmentactiongroup.org/cure/trials. Accessed May 12, 2020
- Genetic Immunity website. DermaVir. https://www.geneticimmunity.com/dermavir.html. Accessed May 12, 2020
- The History of Vaccines website. The development of HIV vaccines. https://www.historyofvaccines.org/content/articles/development-hiv-vaccines. Accessed May 12, 2020
- Graziani GM, Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc. 2015;18(1):20497.
- Genetic Immunity website. Our immune-therapy technology platform. https://www.geneticimmunity.com/products.html. Accessed May 12, 2020
- Rodriguez B, Asmuth DM, Matining RM, et al. Safety, tolerability and immunogenicity of repeated doses of DermaVir, a candidate therapeutic HIV vaccine, in HIV infected patients receiving combination antiretroviral therapy. Results of the ACTG 5176 trial. J Acquir Immune Defic Syndr. 2013;64(4):351-359. doi:10.1097/QAI.0b013e3182a99590
- National Institute of Allergy and Infectious Diseases (NIAID). A Phase I/II, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of LC002, a DermaVir vaccine, in HIV-1-infected subjects currently under treatment with highly active antiretroviral therapy (HAART). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on December 21, 2005. NLM Identifier: NCT00270205. https://www.clinicaltrials.gov/ct2/show/NCT00270205. Accessed May 12, 2020
- Genetic Immunity. A Phase II randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, immunogenicity, and antiretroviral activity of DermaVir patch (LC002) in treatment-naïve HIV-1-infected patients. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on July 4, 2008. NLM Identifier: NCT00711230. https://www.clinicaltrials.gov/ct2/show/NCT00711230. Accessed May 12, 2020
- Genetic Immunity. Antiretroviral-sparing concept: an exploratory Phase II, randomized, single blind placebo-controlled study to investigate the effect of therapeutic immunization on the quantity of HIV-specific T cell precursors during highly active antiretroviral therapy followed by analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on June 8, 2009. NLM Identifier: NCT00918840. https://www.clinicaltrials.gov/ct2/show/NCT00918840. Accessed May 12, 2020
- van Lunzen J, Pollard R, Stellbrink H-J, et al. DermaVir for initial treatment of HIV-infected subjects demonstrates preliminary safety, immunogenicity and HIV-RNA reduction versus placebo immunization. Poster presented at: International AIDS Conference; July 18-23, 2010; Vienna, Austria. https://www.researchgate.net/publication/264848719_DermaVir_for_initial_treatment_of_HIV-infected_subjects_demonstrates_preliminary_safety_immunogenicity_and_HIV-RNA_reduction_versus_placebo_immunization_A-240-0111-_12561. Accessed May 12, 2020
Last Reviewed: May 12, 2020